Top Markets
#1 Islamic Coin Islamic Coin +151.56%
#2 Black Phoenix Black Phoenix +35.83%
#3 Palladium Network Palladium Network +20.31%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.14%
#5 Akedo Akedo +16.13%
#6 Fake World Assets Fake World Assets +12.92%
#7 OpenEden OpenEden +12.68%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.64%
#9 clBTC clBTC +12.01%
#10 Arowana Arowana +11.93%
Coin of the day
Islamic Coin Islamic Coin
Настройки
Язык
Pусский
Валюта
USD
Тема
Bioasis Technologies Inc. Bioasis Technologies Inc.

Bioasis Technologies Inc.

BTI
Ранг среди акций #39945
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Цена акции
$0.00366968
Последняя синхронизация: 2024-07-23
Рыночная капитализация
$291.42K
Изменение (1 день)
-0.81%
Изменение (1 год)
0.00%
Страна
US
Торговля Bioasis Technologies Inc. (BTI)

Категория

Healthcare
Прибыль Bioasis Technologies Inc. (BTI)
Прибыль на 2026 TTM: 0
Согласно последним финансовым отчетам Bioasis Technologies Inc., текущая прибыль компании составляет 0. В 2026 году компания получила прибыль 0, равна прибыли за 2026, которая составила 0. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании Bioasis Technologies Inc. с 2026 по 2026
Прибыль в конце каждого года
Год Прибыль Изменить
Недостаточно данных для указанных дат.
Прибыль схожих компаний или конкурентов
Компания Прибыль Разница в прибыли Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE